The involvement of the immune system in tumor control is becoming well understood. The tumor environment is in a state of equilibrium between the elimination of cancer cells by the immune system and their proliferation. The immuno-evasion mechanisms that allow tumor cells to remain in equilibrium with the host depends on the overexpression of immunoregulatory molecules such as PD-L1 and its interaction with PD-1 expressed on tumor-infiltrating T lymphocytes. Blocking this interaction is being considered as a more targeted therapeutic approach that blocks the interaction of PD-1 with its ligands, leading to various clinical trial using monoclonal antibodies anti-PD-1 or anti-PD-L1 in several types of cancers. In order to develop such therapies, it is imperative to characterize the interaction between PD-1 and PD-L1. In this webinar we will show how we employed MicroScale Thermophoresis (MST) for the quantitative analysis of the binding affinity between these two molecules. Particularly we describe a method that utilizes low sample consumption and no tedious purification step of the protein of interest.
Ready to characterize your most challenging interactions?
Discover tools to measure binding affinity
See more related content
NanoTemper Technologies introduced Monolith X, adding breakthrough Spectral Shift technology to their top-selling Monolith product line.
NanoTemper’s newest Monolith instrument has been awarded the Red Dot Award, an internationally recognized seal of excellence in design. Both bold aesthetics and user-friendly design have always...
Targeted Protein Degradation (TPD), a relatively new therapeutic approach, is making waves by targeting otherwise ‘undruggable’ proteins. PROTACs are the best-understood protein degraders, with...
The desire to use technology that allows you to study membrane proteins in close-to-native conditions is specifically important when it comes to interaction measurements. It’s always a question how mu
Targeted protein degradation using molecular glues or proteolysis-targeting chimeras (PROTACs) is an increasingly important therapeutic modality, especially for undruggable targets. Even with candidat
With PROTACs currently in the clinical and preclinical stages, they are making exciting progress towards successfully treating patients who have been waiting for effective therapies for certain...
SARS-CoV-2, the causative agent of COVID-19, has an ssRNA genome of almost 30kb that encodes for a total of 26 proteins. Among the four structural viral protein, in particular the S protein stands out
Explore the complexities and drivers of molecular interactions with Dr. Tom Laue from the University of New Hampshire. He presented as a keynote speaker in the Protein Stability & Function: Can't have
Dr. Leah Pandiscia and Dr. Daniel Turman review how to integrate the Prometheus Panta and Monolith instruments in a characterization workflow demonstration, showing how to maximize stability and funct
NanoTemper’s newest Monolith instrument has been awarded the globally renowned iF DESIGN AWARD 2021. User-friendly design has always been a core focus in NanoTemper’s product development....
Are you struggling to tame your mischievous membrane proteins? Find out how NanoTemper can help you to characterize even the most challenging membrane protein samples. You will learn how Prometheus ca